The Manufacturers Life Insurance Company Takes Position in Establishment Labs Holdings Inc. $ESTA

The Manufacturers Life Insurance Company purchased a new stake in shares of Establishment Labs Holdings Inc. (NASDAQ:ESTA) in the 2nd quarter, HoldingsChannel.com reports. The firm purchased 12,429 shares of the company’s stock, valued at approximately $1,067,000.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Simplify Asset Management Inc. boosted its holdings in Establishment Labs by 92.1% during the fourth quarter. Simplify Asset Management Inc. now owns 72,894 shares of the company’s stock worth $5,313,000 after buying an additional 34,946 shares in the last quarter. Assenagon Asset Management S.A. grew its position in shares of Establishment Labs by 164.9% during the 2nd quarter. Assenagon Asset Management S.A. now owns 135,897 shares of the company’s stock valued at $11,661,000 after acquiring an additional 84,592 shares during the period. Bank of America Corp DE raised its holdings in Establishment Labs by 56.7% in the 1st quarter. Bank of America Corp DE now owns 416,840 shares of the company’s stock worth $23,668,000 after purchasing an additional 150,797 shares during the period. AlTi Global Inc. purchased a new position in shares of Establishment Labs during the 1st quarter valued at approximately $842,000. Finally, Sigma Planning Corp lifted its stake in Establishment Labs by 325.5% in the 1st quarter. Sigma Planning Corp now owns 20,424 shares of the company’s stock valued at $1,160,000 after buying an additional 15,624 shares in the last quarter. Institutional investors and hedge funds own 72.91% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have recently issued reports on ESTA shares. Needham & Company LLC lifted their price target on Establishment Labs from $86.00 to $95.00 and gave the stock a “buy” rating in a research note on Thursday, August 6th. Citigroup raised shares of Establishment Labs from a “neutral” rating to a “buy” rating and set a $92.00 target price for the company in a report on Thursday, August 13th. Canaccord Genuity Group set a $105.00 price target on Establishment Labs in a research report on Thursday, August 6th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Establishment Labs in a research note on Wednesday, June 24th. Finally, BTIG Research restated a “buy” rating and set a $103.00 price objective on shares of Establishment Labs in a research report on Tuesday. Eight equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $100.25.

Establishment Labs Trading Up 2.8%

ESTA opened at $74.29 on Friday. Establishment Labs Holdings Inc. has a 52 week low of $36.53 and a 52 week high of $97.59. The company has a quick ratio of 2.52, a current ratio of 3.84 and a debt-to-equity ratio of 12.11. The business has a fifty day simple moving average of $83.45 and a 200-day simple moving average of $74.89. The firm has a market cap of $2.21 billion, a P/E ratio of -56.71 and a beta of 1.05.

Establishment Labs (NASDAQ:ESTA) last released its earnings results on Thursday, August 6th. The company reported ($0.39) earnings per share for the quarter, missing the consensus estimate of ($0.34) by ($0.05). Establishment Labs had a negative net margin of 15.82% and a negative return on equity of 196.69%. The firm had revenue of $67.54 million during the quarter, compared to analyst estimates of $65.79 million. During the same period in the prior year, the firm earned ($0.57) earnings per share. The business’s revenue was up 31.7% compared to the same quarter last year. On average, equities analysts expect that Establishment Labs Holdings Inc. will post -1.15 earnings per share for the current year.

Establishment Labs Company Profile

Establishment Labs Holdings Inc is a global medical technology company specializing in the design, development and manufacture of silicone gel breast implants for aesthetic and reconstructive surgery. The company’s proprietary portfolio is built around patient-focused safety, customization and innovation, offering solutions intended to enhance surgical outcomes and support clinical traceability.

The company’s flagship products fall under the Motiva® brand, which includes a range of ergonomic and round breast implants featuring SilkSurface® texturing and an embedded Q Inside® Safety microtransponder for unique implant identification.